EA202191503A1 - Комбинированные терапии для мдс высокого и очень высокого риска - Google Patents

Комбинированные терапии для мдс высокого и очень высокого риска

Info

Publication number
EA202191503A1
EA202191503A1 EA202191503A EA202191503A EA202191503A1 EA 202191503 A1 EA202191503 A1 EA 202191503A1 EA 202191503 A EA202191503 A EA 202191503A EA 202191503 A EA202191503 A EA 202191503A EA 202191503 A1 EA202191503 A1 EA 202191503A1
Authority
EA
Eurasian Patent Office
Prior art keywords
combination therapies
risk mds
high risk
mds
pracinostat
Prior art date
Application number
EA202191503A
Other languages
English (en)
Inventor
Ричард Гали
Original Assignee
Мей Фарма, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мей Фарма, Инк. filed Critical Мей Фарма, Инк.
Publication of EA202191503A1 publication Critical patent/EA202191503A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

В настоящем документе предусмотрены способы лечения МДС высокого и очень высокого риска, предусматривающие введение прациностата и агента, гипометилирующего ДНК.
EA202191503A 2018-11-30 2019-11-26 Комбинированные терапии для мдс высокого и очень высокого риска EA202191503A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862773490P 2018-11-30 2018-11-30
PCT/US2019/063360 WO2020112848A1 (en) 2018-11-30 2019-11-26 Combination therapies for high and very high risk mds

Publications (1)

Publication Number Publication Date
EA202191503A1 true EA202191503A1 (ru) 2021-11-15

Family

ID=70854408

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191503A EA202191503A1 (ru) 2018-11-30 2019-11-26 Комбинированные терапии для мдс высокого и очень высокого риска

Country Status (14)

Country Link
US (1) US20220016082A1 (ru)
EP (1) EP3886865A4 (ru)
JP (1) JP2022511746A (ru)
KR (1) KR20210097157A (ru)
CN (1) CN113412115A (ru)
AU (1) AU2019389004A1 (ru)
BR (1) BR112021010101A2 (ru)
CA (1) CA3121188A1 (ru)
EA (1) EA202191503A1 (ru)
IL (1) IL283464A (ru)
MA (1) MA54322A (ru)
MX (1) MX2021006127A (ru)
SG (1) SG11202105506UA (ru)
WO (1) WO2020112848A1 (ru)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404716B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US20150258068A1 (en) * 2012-10-30 2015-09-17 Mei Pharma, Inc. Combination therapies
EP3258941A4 (en) * 2015-02-17 2018-09-26 Cantex Pharmaceuticals, Inc. Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction

Also Published As

Publication number Publication date
KR20210097157A (ko) 2021-08-06
IL283464A (en) 2021-07-29
US20220016082A1 (en) 2022-01-20
AU2019389004A1 (en) 2021-07-15
JP2022511746A (ja) 2022-02-01
CN113412115A (zh) 2021-09-17
MA54322A (fr) 2021-10-06
CA3121188A1 (en) 2020-06-04
BR112021010101A2 (pt) 2021-08-24
EP3886865A1 (en) 2021-10-06
SG11202105506UA (en) 2021-06-29
MX2021006127A (es) 2021-06-23
WO2020112848A1 (en) 2020-06-04
EP3886865A4 (en) 2022-11-23

Similar Documents

Publication Publication Date Title
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
PH12017501818A1 (en) Fgfr/pd-1 combination therapy for the treatment of cancer
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
MX2018010473A (es) Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73).
EA201792443A1 (ru) МОДУЛЯТОРЫ K-Ras
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
UY36307A (es) Terapias combinadas para el tratamiento del cáncer
MX2019004500A (es) Terapia de combinación para la inhibición de componente de complemeto (c3).
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
MX2017004526A (es) Terapia combinada de anticuerpos biespecificos especificos para fap y dr5 y agentes quimioterapeuticos.
EA201890079A1 (ru) Клеточная система для направленной доставки активного ингредиента
EA201891399A1 (ru) Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний
MX2020003770A (es) Terapias de combinacion para tratar cancer.
MX2017015311A (es) Combinacion de un anticuerpo anti-il-10 y un oligonucleotido tipo cpg-c para tratar cancer.
BR112019001398A2 (pt) métodos para tratamento de câncer de próstata
EA201991818A1 (ru) Лечение рака
EA201890457A1 (ru) Комбинации антитела против ox40 и модулятора tlr4 и их применение
AR104484A1 (es) Anticuerpos anti-psma como agentes terapéuticos
EA201991360A1 (ru) Модифицированные олигонуклеотиды для лечения поликистозной болезни почек
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
EA201990370A1 (ru) Терапия рака, связанная с crebbp
NZ734750A (en) Cancer therapy with a parvovirus combined with bevacizumab
BR112019006504A2 (pt) regime de dosagem de avelumabe para o tratamento de câncer
EA201891419A1 (ru) Пептид-олигонуклеотидные конъюгаты
EA201890623A1 (ru) Рациональная комбинированная терапия для лечения рака